ZFIN ID: ZDB-FIG-190723-2561
Skvarca et al., 2019 - Enhancing acute kidney injury regeneration by promoting cellular dedifferentiation in zebrafish. Disease models & mechanisms   12(4) Full text @ Dis. Model. Mech.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Antibody:
Fish:
Condition:
Anatomical Terms:
Stage Range: Pec-fin to Day 6
PHENOTYPE:
Fish:
Condition:
Observed In:
Stage Range: Pec-fin to Day 6

Fig. 4.

Neutrophil and macrophage populations change in the kidney field after AKI. (A-D) Tg(cdh17:mCherry); Tg(lyz:EGFP) transgenic zebrafish were used for neutrophil analyses. (E-H) Tg(cdh17:mCherry); Tg(mpeg1;dendra2) transgenic zebrafish were used for macrophage analyses. (A,E) Transgenic lines were injected with gentamicin at 3 dpf and imaged at 2 dpi. (B,F) Snapshots of live imaging of lyz+ neutrophils imaged at 1 dpi for 13.5 h (B) and mpeg1+ macrophages imaged at 2 dpi for 19.5 h (F) in a no-injury and gent-AKI setting. Arrows indicate neutrophils or macrophages adjacent to PTs. (C,G) Immunofluorescence co-stain of PTs (red or green) and neutrophils (green) (C) or macrophages (red) (G) in no-injury and gent-AKI at 3 dpi. PTs are outlined in white and adjacent leukocytes are marked with arrows. (D,H) Quantification of neutrophil (D) and macrophage (H) numbers adjacent to the PT before and after injury. MeanNoInjury5dpf=4.24 (N=34) vs Mean2dpi=7.76 (N=34) vs MeanNoInjury6dpf=5.15 (N=34) vs Mean3dpi=11.60 (N=48). Adjacent leukocytes were counted for both no injury and gent-AKI at 1, 2 and 3 dpi (D), and 2 and 3 dpi (H). Data pooled from three biological replicates are shown expressed as mean±s.e.m. One-way ANOVA: *P<0.05, **P<0.01, ***P<0.005. Scale bars: 20 μm.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
Dendra2 pt307Tg ; uwm12Tg control Day 4 macrophage IFL
Day 4 to Day 6 macrophage IFL
pt307Tg ; uwm12Tg chemical treatment by injection: gentamycin Day 4 macrophage IFL
Day 4 to Day 6 macrophage IFL
uwm12Tg ; nz4Tg control Day 6 macrophage IHC
uwm12Tg ; nz4Tg chemical treatment by injection: gentamycin Day 6 macrophage IHC
EGFP nz117Tg control Day 6 neutrophil IHC
nz117Tg chemical treatment by injection: gentamycin Day 6 neutrophil IHC
pt307Tg ; nz117Tg control Pec-fin to Day 5 neutrophil IFL
Day 4 neutrophil IFL
pt307Tg ; nz117Tg chemical treatment by injection: gentamycin Pec-fin to Day 5 neutrophil IFL
Day 4 neutrophil IFL
uwm12Tg ; nz4Tg control Day 6 pronephric duct IHC
uwm12Tg ; nz4Tg chemical treatment by injection: gentamycin Day 6 pronephric duct IHC
Day 6 regenerating tissue pronephric duct IHC
mCherry pt307Tg ; nz117Tg control Pec-fin to Day 5 pronephric tubule IFL
Day 4 pronephric tubule IFL
pt307Tg ; nz117Tg chemical treatment by injection: gentamycin Pec-fin to Day 5 pronephric tubule IFL
Pec-fin to Day 5 regenerating tissue pronephric tubule IFL
Day 4 pronephric tubule IFL
Day 4 regenerating tissue pronephric tubule IFL
pt307Tg ; uwm12Tg control Day 4 pronephric tubule IFL
Day 4 to Day 6 pronephric tubule IFL
pt307Tg ; uwm12Tg chemical treatment by injection: gentamycin Day 4 pronephric tubule IFL
Day 4 regenerating tissue pronephric tubule IFL
Day 4 to Day 6 pronephric tubule IFL
Day 4 to Day 6 regenerating tissue pronephric tubule IFL
Antibody Labeling Details
Antibody Assay Fish Conditions Stage Anatomy
Ab-3G8 IHC nz117Tg control Day 6 pronephric duct
IHC nz117Tg chemical treatment by injection: gentamycin Day 6 pronephric duct
IHC Day 6 regenerating tissue pronephric duct
Phenotype Details
Fish Conditions Stage Phenotype
nz117Tg chemical treatment by injection: gentamycin Day 6 neutrophil activation involved in immune response increased occurrence, abnormal
Day 6 pronephric duct neutrophil increased amount, abnormal
Day 6 regenerating tissue neutrophil increased amount, abnormal
pt307Tg ; nz117Tg chemical treatment by injection: gentamycin Pec-fin - Day 5 neutrophil activation involved in immune response increased occurrence, abnormal
Pec-fin - Day 5 pronephric duct neutrophil increased amount, abnormal
Pec-fin - Day 5 regenerating tissue neutrophil increased amount, abnormal
Day 4 neutrophil activation involved in immune response increased occurrence, abnormal
Day 4 pronephric duct neutrophil increased amount, abnormal
Day 4 regenerating tissue neutrophil increased amount, abnormal
pt307Tg ; uwm12Tg chemical treatment by injection: gentamycin Day 4 macrophage activation involved in immune response increased occurrence, abnormal
Day 4 pronephric duct macrophage increased amount, abnormal
Day 4 regenerating tissue macrophage increased amount, abnormal
Day 4 - Day 6 macrophage activation involved in immune response increased occurrence, abnormal
Day 4 - Day 6 pronephric duct macrophage increased amount, abnormal
Day 4 - Day 6 regenerating tissue macrophage increased amount, abnormal
uwm12Tg ; nz4Tg chemical treatment by injection: gentamycin Day 6 macrophage activation involved in immune response increased occurrence, abnormal
Day 6 pronephric duct macrophage increased amount, abnormal
Day 6 regenerating tissue macrophage increased amount, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Disease models & mechanisms for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Dis. Model. Mech.